Antitumor effects of gefitinib for metastatic brain tumors from lung carcinomas with EGFR mutation

Neurological Surgery

Volumn 39, Issue 6, 2011, Pages 569-574

  Ono, Yasuhiro ^a   Toyota, Yasunori ^a   Toyoshima, Atsuhiko ^a   Kuramoto, Satoshi ^a   Katzumata, Atsushi ^a   Kawauchi, Masamitsu ^a   Matsumoto, Yuzo ^a  

^a KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Chemotherapy; EGFR mutation; Gefitinib; Lung cancer; Metastatic brain tumor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN METASTASIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG EFFICACY; EXON; GENE MUTATION; HUMAN; LUNG CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; QUINAZOLINES;

EID: 79959340582     PISSN: 03012603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Clarke JL, Pao W, Wu N, Miller VA, Lassman AB : High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 99 : 283-286, 2010
2. Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, Kwiatkowski DJ, Engelman JA, Janne PA : Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 29 : 2346-2356, 2010
3. Japan clinical oncology group : National Cancer Institute-Common Toxicity Criteria (NCI-CTC Version 3.0, 2004) - JCOG -. pp1-82 (Japan clinical oncology group : National Cancer Institute-Common Toxicity Criteria, 2004)
4. Katayama T, Shimizu J, Suda K, Onozato R, Fukui T, Ito S, Hatooka S, Sueda T, Hida T, Yatabe Y, Mitsudomi T : Efficacy of erlotinib for brain and leptomeningeal metastasis in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 4 : 1415-1419, 2009
5. Kim JE, Lee DH, Choi T, Yoon DH, Kim SW, Suh C, Lee JS : Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 65 : 351-354, 2009
6. Lynch TJ, Bell DW, Sordella R, Gurubhagevatula S, Okimoto RA, Harris PL, Haserlat SM, Supuko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA : Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 : 2129-2139, 2004 (Pubitemid 38637993)
7. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T : Gefitinib or chrmotherapy for non-small cell lung cancer with mutated EGFR. N Engl J Med 362 : 2380-2388, 2010
8. Mitudomi T, Yatabe Y : Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98 : 1817-1824, 2007
9. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaya FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M : EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy. Science 304 : 1497-1500, 2004 (Pubitemid 38720929)
10. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M. for the Spanish Lung Cancer Group : Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361 : 958-967, 2009
11. Shimato S, Mitsudomi T, Kosaka T, Yatabe Y, Wakabayashi T, Mizuno M, Nakahara N, Hatano H, Natsume A, Ishii D, Yoshida J : EGFR mutations in patients with brain metastases from lung candcer : association with the efficacy of gefitinib. Neuro Oncol 8 : 137-144, 2006 (Pubitemid 46542658)